21 July 2022  
EMA/639016/2022  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Imcivree 
setmelanotide 
On 21 July 2022,  the Committee for Medicinal  Products for Human Use (CHMP)  adopted a positive opinion 
recommending a change to  the terms of the marketing authorisation for the medicinal product  Imcivree2. 
The marketing authorisation holder for this  medicinal product is  Rhythm Pharmaceuticals Netherlands 
B.V. 
The CHMP adopted a new indication to include treatment of obesity and hunger control in patients  with 
Bardet-Biedl syndrome (BBS). 
For information, the full indications  for Imcivree will therefore be as follows3: 
IMCIVREE is indicated for the treatment of obesity and the control of hunger associated with 
genetically confirmed Bardet-Biedl  syndrome (BBS),  loss-of-function biallelic pro-
opiomelanocortin (POMC),  including PCSK1, deficiency or biallelic leptin receptor (LEPR) 
deficiency in adults and children 6 years of age and above. 
Detailed recommendations for the use of this  product will be described in the updated summary of 
product characteristics (SmPC), which will  be published in the  revised European public assessment report 
(EPAR), and will be available in all official European Union  languages after a decision on this change to 
the marketing authorisation has been granted by the  European Commission.  
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 This product was designated as an orphan medicine during its development. EMA will now review the information available to 
date to determine if the orphan designation can be maintained  
3 new text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European  Union    
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
